New Drug Screening Center, Jiangsu Center for Pharmacodynamics Research and Evaluation, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University, Nanjing, 210009, China.
Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), China Pharmaceutical University, Nanjing, 210009, China.
Curr Pharm Des. 2023;29(8):620-629. doi: 10.2174/1381612829666230313111314.
Mitochondria are multifunctional organelles, which participate in biochemical processes. Mitochondria act as primary energy producers and biosynthetic centers of cells, which are involved in oxidative stress responses and cell signaling transduction. Among numerous potential mechanisms of mitochondrial dysfunction, the opening of the mitochondrial permeability transition pore (mPTP) is a major determinant of mitochondrial dysfunction to induce cellular damage or death. A plenty of studies have provided evidence that the abnormal opening of mPTP induces the loss of mitochondrial membrane potential, the impairment calcium homeostasis and the decrease of ATP production. Cyclophilin D (CypD), localized in the mitochondrial transition pore, is a mitochondrial chaperone that has been regarded as a prominent mediator of mPTP.
This review describes the relationship between CypD, mPTP, and CypD-mPTP inhibitors through systematic investigation of recent relevant literature.
Here, we have highlighted that inhibiting the activity of CypD protects models of some diseases, including ischaemia/reperfusion injury (IRI), neurodegenerative disorders and so on. Knockdown studies have demonstrated that CypD possibly is mediated by its peptidyl-prolyl cis-trans isomerase activity, while the primary targets of CypD remain obscure. The target of CypD-mPTP inhibitor can alleviate mPTP opening-induced cell death. The present review is focused on the role of CypD as a prominent mediator of the mPTP, further providing insight into the physiological function of mPTP and its regulation by CypD.
Blocking the opening of mPTP by inhibiting CypD might be a new promising approach for suppressing cell death, which will suggest novel therapeutic approaches for mitochondria-related diseases.
线粒体是多功能细胞器,参与生化过程。线粒体作为细胞的主要能量产生和生物合成中心,参与氧化应激反应和细胞信号转导。在众多潜在的线粒体功能障碍机制中,线粒体通透性转换孔(mPTP)的开放是导致线粒体功能障碍、诱导细胞损伤或死亡的主要决定因素。大量研究已经提供了证据,证明 mPTP 的异常开放导致线粒体膜电位丧失、钙稳态受损和 ATP 产生减少。亲环素 D(CypD)位于线粒体转换孔,是一种线粒体伴侣蛋白,被认为是 mPTP 的主要介体。
本综述通过系统研究最近的相关文献,描述了 CypD、mPTP 之间的关系,以及 CypD-mPTP 抑制剂。
在这里,我们强调了抑制 CypD 的活性可以保护缺血/再灌注损伤(IRI)、神经退行性疾病等疾病的模型。敲低研究表明,CypD 可能通过其肽基脯氨酰顺反异构酶活性介导,而 CypD 的主要靶标仍不清楚。CypD-mPTP 抑制剂的靶标可以减轻 mPTP 开放诱导的细胞死亡。本综述重点介绍了 CypD 作为 mPTP 的主要介体的作用,进一步深入了解 mPTP 的生理功能及其受 CypD 的调节。
通过抑制 CypD 阻断 mPTP 的开放可能是抑制细胞死亡的一种新的有前途的方法,这将为与线粒体相关的疾病提供新的治疗方法。